RAM
NGNE icon

Readystate Asset Management’s Neurogene NGNE Stock Holding History

Readystate Asset Management’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-31,711
Closed -$474K – 580
2025
Q2 		$474K Buy
+31,711
New +$498K 0.01% 384

Other funds holding NGNE

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Readystate Asset Management's NGNE Position: Q3 2025 in Review

Readystate Asset Management sold out of Neurogene (NGNE) in Q3 2025, closing a stake of 31,711 shares — an estimated $474K sold.

Readystate Asset Management first reported a position in NGNE in Q2 2025 and held it in 1 quarter. The position peaked at $474K in Q2 2025. 88 funds tracked by Wall St. Rank hold NGNE as of Q3 2025.

  • Readystate Asset Management reported no remaining Neurogene position as of Q3 2025 after selling out during the quarter.
  • Readystate Asset Management sold 31,711 Neurogene shares in Q3 2025, an estimated $474K.
  • Readystate Asset Management first reported a position in Neurogene in Q2 2025 and held it in 1 quarter.
  • Readystate Asset Management's Neurogene position peaked at $474K in Q2 2025.
  • 88 funds tracked by Wall St. Rank held Neurogene as of Q3 2025.

Based on Readystate Asset Management's 13F filing for Q3 2025, filed 7 Nov 2025.